The effects of PEGylation on LNP based mRNA delivery to the eye
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Gene therapy is now an effective approach to treat many forms of retinal degeneration. Delivery agents that are cell-specific, allow for multiple dosing regimens, and have low immunogenicity are needed to expand the utility of gene therapy for the retina. We generated eight novel lipid nanoparticles (LNPs) ranging in size from 50 nm to 150 nm by changing the PEG content from 5% to 0.5%, respectively. Subretinal injections of LNP-mRNA encoding luciferase revealed that 0.5% PEG content within nanoparticles elicits the highest expression. Similar injections of LNP delivered cre mRNA into Ai9 mice revealed cell-specific protein expression in the retinal pigment epithelium (RPE), confirmed by fundus photography and immunohistochemistry of whole globe cross-sections. To investigate mechanisms of LNP delivery to the eye, we injected mCherry mRNA using the subretinal approach in apoE-/- and Mertk-/- mice. RPE transfection was observed in both mouse models suggesting that LNP intracellular delivery is not solely dependent on apolipoprotein adsorption or phagocytosis. To investigate LNP penetration, particles were delivered to the vitreous chamber via an intravitreal injection. The 0.5% PEG particles mediated the highest luciferase activity and expression was observed in the Müller glia, the optic nerve head and the trabecular meshwork, but failed to reach the RPE. Overall, particles containing less PEG (~150 nm in size) mediated the highest expression in the eye. Thus far, these particles successfully transfect RPE, Müller cells, the optic nerve head and the trabecular meshwork based on route of administration which can expand the utility of LNP-mediated gene therapies for the eye.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [90]
Experimental — accuracy not yet measuredIn the citing paper
“The PEG-molecules at the surface prevent the individual LNPs from aggregating.”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Ryals et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907
Cellular uptake of nanoparticles: Journey inside the cell
Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859 · cited 2×
“In general, particles<500 nm are internalized via endocytosis, whereas particles >1000 nm utilize phagocytosis [22, 23].”
BackgroundResultEngineered nanoparticles interacting with cells: size matters
Shang, L., Nienhaus, K., & Nienhaus, G. U. (2014) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-12-5 · Cited by 1,316
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · cited 3×
“This was established by observing diminished LNP transfection efficiency in both apoE and LDLR mice [27].”
BackgroundLipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
(1984) · PubMed · Cited by 1,200
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Müller glial cell reprogramming and retina regeneration
Goldman, D. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3723 · Cited by 625
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592
Yanez Arteta, M., Kjellman, T., Bartesaghi, S., Wallin, S., Wu, X., Kvist, A. J., Dabkowska, A., Székely, N., Radulescu, A., Bergenholtz, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720542115 · Cited by 534
Vranka, J. A., Kelley, M. J., Acott, T. S., & Keller, K. E. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2014.07.014 · Cited by 393
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E., & Sahay, G. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.015 · Cited by 260
Self-citationAn RCS-Like Retinal Dystrophy Phenotype in Mer Knockout Mice
Duncan, J. L., LaVail, M. M., Yasumura, D., Matthes, M. T., Yang, H., Trautmann, N., Chappelow, A. V., Feng, W., Earp, H. S., Matsushima, G. K., et al. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0438 · Cited by 259
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257
Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA
Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K. E., Mihai, C., Almarsson, Ö., & Sahay, G. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b02664 · Cited by 251 · cited 1×
“Although cholesterol has been closely linked to enhancing endosomal escape [33], our data suggest that in the retina having more cholesterol potentially on the surface could enhance penetration, which could be linked to protein adsorption as the particle moves through the retina.”
BackgroundSelf-citationAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Wang, F., Kream, R. M., & Stefano, G. B. (2020) · Medical Science Monitor · doi:10.12659/msm.924700 · Cited by 243
Song, L. Y., Ahkong, Q. F., Rong, Q., Wang, Z., Ansell, S., Hope, M. J., & Mui, B. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00399-6 · Cited by 228
Understanding photoreceptor outer segment phagocytosis: use and utility of RPE cells in culture
Mazzoni, F., Safa, H., & Finnemann, S. C. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.01.010 · Cited by 221
The outer limiting membrane (OLM) revisited: clinical implications
Behar-Cohen, F. (2010) · Clinical Ophthalmology · doi:10.2147/opth.s5901 · Cited by 199
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189 · cited 1×
“The vehicle, once delivered to the vitreous chamber, will have to move through the vitreous humor, which is composed of collagen, hyaluronan, glycosaminoglycans, and a cocktail of various proteins which restrict diffusion [14].”
BackgroundSubretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases
Peng, Y., Tang, L., & Zhou, Y. (2017) · Ophthalmic Research · doi:10.1159/000479157 · Cited by 175 · cited 1×
“Specific to treating the retina, clinicians and scientists are in much debate over the visual impact of detaching the fovea and/or a fragile degenerating retina during a subretinal injection [6].”
BackgroundA novel cationic niosome formulation for gene delivery to the retina
Puras, G., Mashal, M., Zárate, J., Agirre, M., Ojeda, E., Grijalvo, S., Eritja, R., Diaz-Tahoces, A., Martínez Navarrete, G., Avilés-Trigueros, M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.004 · Cited by 164
Roska, B., & Sahel, J.-A. (2018) · Nature · doi:10.1038/s41586-018-0076-4 · Cited by 161
Effect of Particle Size of Polymeric Nanospheres on Intravitreal Kinetics
Sakurai, E., Ozeki, H., Kunou, N., & Ogura, Y. (2001) · Ophthalmic Research · doi:10.1159/000055638 · Cited by 155
Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes
Bao, Y., Jin, Y., Chivukula, P., Zhang, J., Liu, Y., Liu, J., Clamme, J., Mahato, R. I., Ng, D., Ying, W., et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0874-6 · Cited by 127
Apaolaza, P. S., del Pozo‐Rodríguez, A., Solinís, M. Á., Rodríguez, J. M., Friedrich, U., Torrecilla, J., Weber, B. H. F., & Rodríguez‐Gascón, A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.004 · Cited by 97
Intravitreal nanoparticles for retinal delivery
Huang, X., & Chau, Y. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.005 · Cited by 86
Ameri, H. (2018) · Journal of Current Ophthalmology · doi:10.1016/j.joco.2018.01.006 · Cited by 75
Structure and composition of the inner limiting membrane of the retina
Heegaard, S., Jensen, O. A., & Prause, J. U. (1986) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf02150029 · Cited by 66
Sanders, N. N., Peeters, L., Lentacker, I., Demeester, J., & Smedt, S. C. D. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.004 · Cited by 63
Suprachoroidal gene transfer with nonviral nanoparticles
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A. (2020) · Science Advances · doi:10.1126/sciadv.aba1606 · Cited by 63
Tai, L., Liu, C., Jiang, K., Chen, X., Feng, L., Pan, W., Wei, G., & Lu, W. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.090 · Cited by 39
Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness
Patel, U. A., Boucher, M., de Léséleuc, L., & Visintini, S. M. (2016) · Europe PMC (PubMed Central) · Cited by 34
Post-Vitrectomy Endophthalmitis in Victoria, Australia
Chandra, A., Smith, J. D., Wang, B. Z., Kurniawan, E. D., Kam, J., Sandhu, S. S., & Allen, P. J. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2016126 · Cited by 28
Adams, D., & Ole, S. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.01.085 · Cited by 11
In Vivo Small Molecule Delivery to the Optic Nerve in a Rodent Model
Tehrani, S., Delf, R. K., Cepurna, W. O., Davis, L., Johnson, E. C., & Morrison, J. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-22737-4 · Cited by 5
An option for treatment of multidrug-resistant HIV
Stower, H. (2018) · Nature Medicine · doi:10.1038/s41591-018-0191-7 · Cited by 5
Restoring sight with native cell reprogramming
Stower, H. (2018) · Nature Medicine · doi:10.1038/s41591-018-0192-6 · Cited by 3
Research works printed but not linked: 2
- C Kay, 2019, Retinal Gene Therapies in Clinical Trials A proliferation of clinical trials means hope for patients, Retinal Physician, 16, 36
- T Borrás, 2017, The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs., Asia Pac J Ophthalmol (Phila)., 6, 80
Cited by
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 873
Self-citationThe clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Metadata
- Authors
- Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G.
- Affiliations
- Oregon Health & Science University (US)
- Oregon State University (US)
- Corresponding author
- Sahay, Gaurav
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-10-29
- Volume
- 15
- Issue
- 10
- Pages
- e0241006
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7595320
- OpenAlex
- W3096490487
- Cited by
- 194
- References
- 40
- Citations by year
- 2026: 30 · 2025: 42 · 2024: 32 · 2023: 37 · 2022: 35 · 2021: 17 · 2020: 1
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (P30 EY010572)
- National Eye Institute (1R21EY031066-01A1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- PEGylation, lipid nanoparticles, mRNA delivery, ocular gene therapy, retinal degeneration, subretinal injection, intravitreal injection, retinal pigment epithelium, apolipoprotein E, MERTK, Müller cells, optic nerve head, trabecular meshwork, particle size
- MeSH terms
- Mice, Knockout, ApoE, Red Fluorescent Protein, Animals, Female, Fundus Oculi, Lipids, Luminescent Proteins, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Particle Size, Polyethylene Glycols, RNA, Messenger, Drug Delivery Systems, Gene Transfer Techniques, Nanoparticles, Retinal Pigment Epithelium, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.